Tempero MA - Search Results

1

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. Ko AH, et al. Among authors: tempero ma. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):809-16. doi: 10.1016/j.ijrobp.2007.01.005. Epub 2007 Mar 23. Int J Radiat Oncol Biol Phys. 2007. PMID: 17363191 Clinical Trial.

2

Current and future strategies for combined-modality therapy in pancreatic cancer.

Ko AH, Tempero MA. Ko AH, et al. Among authors: tempero ma. Curr Oncol Rep. 2002 May;4(3):202-12. doi: 10.1007/s11912-002-0017-z. Curr Oncol Rep. 2002. PMID: 11937010 Review.

3

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Tempero M, et al. J Clin Oncol. 2003 Sep 15;21(18):3402-8. doi: 10.1200/JCO.2003.09.140. Epub 2003 Jul 28. J Clin Oncol. 2003. PMID: 12885837 Clinical Trial.

4

Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.

Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Blackstock AW, et al. Among authors: tempero ma. Int J Gastrointest Cancer. 2003;34(2-3):107-16. doi: 10.1385/ijgc:34:2-3:107. Int J Gastrointest Cancer. 2003. PMID: 15361643 Clinical Trial.

5

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Ko AH, et al. Among authors: tempero ma. Br J Cancer. 2005 Jul 25;93(2):195-9. doi: 10.1038/sj.bjc.6602687. Br J Cancer. 2005. PMID: 15999098 Free PMC article. Clinical Trial.

6

Systemic therapy for pancreatic cancer.

Ko AH, Tempero MA. Ko AH, et al. Among authors: tempero ma. Semin Radiat Oncol. 2005 Oct;15(4):245-53. doi: 10.1016/j.semradonc.2005.06.001. Semin Radiat Oncol. 2005. PMID: 16183478 Review.

7

Treatment of metastatic pancreatic cancer.

Ko AH, Tempero MA. Ko AH, et al. Among authors: tempero ma. J Natl Compr Canc Netw. 2005 Sep;3(5):627-36. doi: 10.6004/jnccn.2005.0036. J Natl Compr Canc Netw. 2005. PMID: 16194454 Review.

8

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Ko AH, et al. Among authors: tempero ma. J Clin Oncol. 2006 Jan 20;24(3):379-85. doi: 10.1200/JCO.2005.01.8267. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344320 Clinical Trial.

9

Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Ko AH, et al. Among authors: tempero ma. Cancer Invest. 2008 Feb;26(1):47-52. doi: 10.1080/07357900701681483. Cancer Invest. 2008. PMID: 18181045 Clinical Trial.

10

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. Ko AH, et al. Among authors: tempero ma. Invest New Drugs. 2008 Oct;26(5):463-71. doi: 10.1007/s10637-008-9127-2. Epub 2008 Apr 1. Invest New Drugs. 2008. PMID: 18379729 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

273 results

Search Page

Filters